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Abstract
The epithelial–mesenchymal transition (EMT) is a molecular process connected to higher expression of vimentin and 
increased activity of transcription factors (Snail, Twist) which restrains E-cadherin. EMT has been linked to prostate cancer 
metastatic potential, therapy resistance, and poor outcomes. Kinetin riboside (9-(b-dribofuranosyl)-6-furfurylaminopurine, 
KR) is a naturally occurring cytokinin, which induces apoptosis and shows strong antiproliferative activity against various 
human cancer cell lines. To establish the effect of KR on human prostate cell lines, expression of, e.g. AR, E-, N-cadherins, 
Vimentin, Snail, Twist, and MMPs, was analysed at mRNA and protein levels using Western Blot and RT-PCR and/or RQ-
PCR techniques. KR inhibited the growth of human prostate cancer cells, but also, to a small extent, of normal cells. This 
effect depended on the type of the cells and their androgen sensitivity. KR also decreased the level of p-Akt, which takes part 
in androgen signalling modulation. The antiapoptotic Bcl-2 protein was down-regulated in cancer cell lines, while that of 
Bax is up-regulated upon KR exposure. KR contributed to re-expression of the E-cadherin as well as to significant changes 
in cell migration. Taken together, our results indicate for the first time that KR can be proposed as a factor for signalling 
pathways regulation that participates in the inhibition of development of aggressive forms of prostate cancer, and may alter 
the approach to therapeutic interventions. We propose KR as a potent inhibitor of EMT in human prostate cells.
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Introduction
According to the data provided by National Cancer Insti-
tute [1] in 2019, prostate cancer (PC) stands for 9.9% of all 
new cancer cases and is responsible for as many as 5.2% 
of all cancer deaths. Currently, one of the most commonly 
employed treatments for high-risk localised and locally 
advanced PC is androgen deprivation therapy (ADT) [2]. It 
is based on great dependence of PC development on andro-
gen influence [3]. Although initial PC response to ADT may 
involve 80% cases, its duration usually lasts beyond 12 to 
18 months [4], implying the need of introducing second 
line therapy, as well as a significantly worsening prognosis. 
Failure of ADT defines a castration-resistant prostate cancer 
(CRPC), a tumour that grows independently of exogenous 
androgens. At molecular level, this transformation may 
involve different patterns such as androgen receptor (AR) 
gene mutation or amplification, changes in expression of AR 
coregulators, increased expression of steroidogenic enzymes, 
increase in signalling through pathways that activate AR 
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independently of androgens, as well as augmented signalling 
that bypasses AR [5]. Apart from acquiring resistance to 
ADT, androgen independence (AI) development also grants 
an independent survival advantage for PC. Interestingly, AR 
may also facilitate negative impact during PC progression 
[6], and thus a release from AR dependence; the following 
loss of the receptor expression may actually be beneficial for 
cancer. AI was described to develop in androgen-sensitive 
LNCaP prostate cancer cell line upon androgen deprivation, 
which was accompanied with enhanced proliferation rate, 
invasiveness, metastasis formation, and induction of epithe-
lial–mesenchymal transition [7].
Alongside AI, epithelio-mesenchymal transition (EMT) 
was described as a vital part of PC development. It was 
linked to PC invasiveness, distant metastasis formation, 
chemoresistance, and poor clinical outcomes, proving its 
importance in disease progression [8]. Moreover, although 
EMT incidence in PC cells is sometimes attributed to andro-
gen influence, it was also shown to be closely related to and 
enhanced by androgen independence development [8]. EMT 
was primarily described as a physiological process inherent 
to cellular differentiation during embryogenesis [8]. How-
ever, it is also involved in tissue morphogenesis, wound heal-
ing, and in pathological possesses such as fibrosis and cancer 
progression. It is also supposed to take part in many different 
diseases [9]. EMT is basically characterised by loss of epi-
thelial cellular traits with subsequent gain of mesenchymal 
ones. These include loss of cellular polarity and adhesion, 
cytoskeleton and cellular junctions reorganisation, as well 
as increased cellular motility [9]. A lot of research was con-
ducted to track molecular changes associated with EMT and 
those that govern this process. Among them, activation of 
transcription factors (TFs) like Snail, Slug, Twist, and Zeb2 
seems to play a central role [9]. It seems that components of 
many molecular pathways including TGFβ, integrins, c-Src, 
Fak, PI3K-Akt, Rac, cdc42, MAPKs, mTOR, RTKs, GSK3β, 
β-catenin, Notch, Hedgehog, HIF1α, NfχB, as well as reac-
tive oxygen species (ROS) may converge at these four TFs 
to regulate EMT [10]. Upon activation by either signalling 
pathway or epigenetic changes, Snail, Slug, Twist, and Zeb1 
mediate changes in gene expression allowing epithelial cells 
to gain mesenchymal traits. Some of such changes governed 
by these TFs are up-regulation of vimentin, matrix metal-
loproteinases (MMPs) and N-cadherin (N-cad) with subse-
quent down-regulation of E-cadherin, (E-cad), cytokeratins, 
claudins and occludins [10]. In case of cancer cells, these 
together promote invasiveness, metastatic potential, treat-
ment resistance, and probably cancer stem cell phenotype, 
and may be implicated in tumour dormancy [9]. Further-
more, EMT may play a vital role in the biology of circulating 
tumour cells (CTCs)—a subpopulation of cancer cells able 
to survive in patient blood and possibly to spread to distant 
organs to form metastases [9]. Importantly, EMT in cancer is 
a reversible process and undergoing mesenchymal–epithelial 
transition (MET) may be required for CTCs to form metas-
tases [9]. It is also a matter of concern what the prime signal 
to induce EMT is as both extracellular (f.i. TGFβ, MMPs, 
ROS) and intracellular cues take part in EMT amplifying 
one another. For many cancer types including PC, it was 
also suggested that stromal cells may play a pivotal role in 
EMT initiation via a close crosstalk with tumour cells [11]. 
Last but not least, further level of complexity is reached 
with the description of partial EMT phenotypes, which may 
be an even more widespread and important phenomenon in 
cancer [9].
Due to the importance of metastasis in pathophysiology 
of cancer disease and mortality associated with it, there is a 
need to find novel factors that inhibit tumour cell invasion. 
Because of the regulation of cellular signalling, and on the 
basis of the results obtained in previous work [12], kinetin 
riboside seems to be a promising factor in this search.
N6-furfuryladenine, also known as kinetin (K), was 
described in 1955 as the first compound from the group of 
cytokinins—natural substances produced by plants known 
for their role in promoting proliferation and possibly differ-
entiation of cells. Kinetin riboside (KR), in turn, is a ribo-
sylated form of the former. Both compounds are thought to 
be generated in vivo in a reaction between hydroxyl radical 
and DNA following modified nucleotides excision. It was 
also suggested that this reaction could serve as a protective 
mechanism for cells to scavenge furfural generated upon 
DNA oxidation stress [13]. For years, a large number of 
research indicated biological activity of the aforementioned 
compounds in animals. Interestingly, while antiaging, pro-
proliferative, antioxidative properties were attributed to 
cytokinins [14], respective ribosilated forms were shown to 
possess rather opposing effects leading to induction of DNA 
damage response genes, increased ROS generation and ATP 
depletion, growth arrest, and apoptosis [15–18]. Importantly, 
the latest was proved in some papers to be at least partially 
specific to cancer cells [19]. Although K and KR are mainly 
described as plant-derived substances, recent evidence 
raised a possibility that they could be generated in humans 
as K was shown to be present in lung cancer patients’ urine 
at levels 100-fold greater than in healthy subjects’ samples 
suggesting an increased generation of K in the first group 
[20]. Importantly, that supports the idea of close relations 
between cancer and K, as well as its derivatives.
In this study, we aim to elucidate the influence of KR 
treatment on PC cell lines in vitro, especially in the context 
of EMT traits and AI.
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Methods
Cell culture
Human prostate cell lines (American Type Culture Collec-
tion—ATCC, Manassas, Virginia, USA)—PZHPV-7 and 
RWPE-1 (both derived from normal prostate peripheral 
zone epithelial cells), WPMY-1 (derived from stroma of 
normal prostate) as well as human prostate cancer cell 
lines (ATCC)—LNCaP (androgen-dependent cell line 
derived from lymph nodes metastasis), PC-3 (androgen-
independent cell line derived from bone metastasis) and 
Du-145 (androgen-independent cell line derived from 
brain metastasis). Cells were cultured in prepared media 
as follows: for non-cancerous PZHPV-7 and RWPE-1 in 
Keratinocyte Serum Free Medium (K-SFM) enriched with 
BPE (0.05 mg/ml) and EGF (5 ng/ml), for WPMY-1 in 
Dulbecco’s Modified Eagle’s Medium with 5% FBS and 
for cancerous cell lines in RPMI-1640 with the addition 
of 10% FBS according to previously described procedure 
[12].
Primary cell line
The prostate tissue samples used in the study were surgi-
cally resected specimens (Department of Urology, Jagiel-
lonian University Medical College, Krakow, Poland) from 
patients with diagnosed and histopathologically confirmed 
(Department of Pathology, Jagiellonian University, Medical 
College, Krakow, Poland [Consent of the Bioethics Com-
mittee])) as normal prostate tissue (n = 11; age 72 ± 10) or 
prostate cancer (CA, G1 n = 6, G2 n = 9, G3 n = 11, G4 n = 9; 
age 64 ± 10). The preparation of tissue slices was performed 
as previously described [21]. Twelve of the obtained tissue 
specimens showed satisfactory growth of the released cells 
and as a result five primary cell lines: normal (N), G1, G2, 
G3, and G4 (obtained from tissues with different grading of 
prostate cancer according to Gleason score) were derived. 
Kinetin riboside (KR) solutions in indicated concentrations 
were prepared as described previously [12], KR (Sigma) was 
dissolved in water to the concentration of 1 mM. Cells were 
treated with prepared dilutions of KR at final concentration 
of 2.5 or 5 μM in full growth media for given amounts of 
time for 48 or 72 h. Non-treated cells were used as a nega-
tive control. Cell culturing and stimulation were conducted 
according to previously described procedure [22].
Cytotoxixity of KR
Cells were seeded in triplicate into 96-well plate in the 
amount of 1.5 × 103 per well and incubated in the presence 
of KR at different evaluated concentrations and cultured 
for 48 and 72 h in standard conditions. Cytotoxicity was 
evaluated based on colorimetric measurement according 
to manufacturer’s instruction (Cytotoxicity Detection Kit, 
Roche Diagnostics, Poland) and previously described pro-
cedure [23]. Absorbance was measured at 492 nm by ELISA 
reader (Synergy HT, BIO-TEK, USA). No cytotoxic effect 
was noted for evaluated concentrations.
Cell proliferation
Cells were seeded in triplicate into 96-well plate in the 
amount of 1.5 × 103 per well and incubated with or with-
out evaluated stimulants at different concentrations. ELISA 
BrdU (Roche) colorimetric immunoassay tests were per-
formed according to manufacturer’s protocol as previously 
described [23]. Cell proliferation was evaluated based on 
absorbance measurement at λ = 450 nm performed with the 
use of ELISA plate reader (Synergy HT, BIO-TEK, USA).
Western blot
After incubation with indicated factors cells were harvested 
in lysis buffer (0.0625 M Tris/HCl pH: 6.8, 2% SDS, 10% 
glycerol, 5% β-mercaptoethanol) and total protein concentra-
tion was evaluated according to Pedersen protocol. Lysates 
containing equal amounts of protein were separated in 10% 
SDS-PAGE gel and transferred onto PVDF membrane. For 
protein detection specific primary antibodies against: AR, 
p-AR(Ser210/213), E-cad, p-Ecad(Ser838/Ser840), AKT, 
p-AKT(Ser 473), PTEN, p-PTEN(Ser380), RAS, RAF, 
ERK1/2, BAX, BAD, BCL-2, SNAIL, TWIST, ZEB1 and 
β-actin (Sigma-Aldrich, Poland) as for referral protein were 
used. Secondary rabbit or mouse antibodies conjugated with 
HRP (1:10,000, Cell Signaling Technology, Inc.) were uti-
lised for detection. All steps were performed as previously 
described [22]. In order to obtain quantitative results, the 
bands (representing each data point) were densitometrically 
scanned using SynGene Gene Tools version 4.03.0 (Synop-
tics Ltd Beacon House, Nuffield Road Cambridge, CB4 1TF, 
UK). β-actin was used as a control. Protein level within the 
control group was arbitrarily set as 1. The procedure was 
performed as previously described [24].
RNA isolation, cDNA synthesis and detection
Total amount of RNA was isolated using RNeasy Plus Mini 
kit (Qiagen, Hilden, Germany) according to manufactur-
er’s instruction. The amount of total RNA was assessed in 
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spectrophotometric measurement (NanoDrop Technologies, 
Wilmington, DE, USA). cDNA synthesis was conducted 
with the use of oligo(dT) starters and GoScript Transcriptase 
(Promega GmbH, Germany) according to provided proto-
col. Prepared cDNA was utilised for the assessment of gene 
expression at the mRNA level utilising Color OptiTaq PCR 
Master Mix (2×) (EURx, Poland) according to manufac-
turer’s instruction. Measurements were performed as previ-
ously described [22]. For primers used in the study PCR 
conditions were applied as follows: initial denaturation at 
95 °C for 5 min; followed by 30 cycles: 30 s at 95 °C, 30 s 
at 58 °C (45 s at 55 °C for AR) and 30 s at 72 °C; and 
final extension at 72 °C for 10 min. Electrophoresis in the 
1.5% agarose gel containing ethidium bromide was used for 
PCR product visualisation. Bands were normalised using 
GAPDH. Utilised primers’ sequences are presented in Sup-
plementary Materials (Table S1). Primers were manufac-
tured by Sigma-Aldrich (St. Louis, MO, USA). Fluorescence 
signal of ethidium bromide was detected by Bio-Rad Chemi-
Doc™ XRS + System (Bio-Rad, Hercules, CA, USA).
Real‑time (RQ‑PCR) analysis
RQ-PCR was performed using 7500 Real-Time PCR Sys-
tem (Applied Biosystems, Foster City, USA) and TaqMan 
probes. Specific primers and probes for AR, BAD, BAX, 
BCL-2, Snail, ZEB1 and ABL (control) genes were pur-
chased from TIB MOLBIOL (Poznan, Poland) and Applied 
Biosystems (Cheshire, UK). RQ-PCR protocols were opti-
mised for each studied gene according to the specific anneal-
ing temperatures (GAPDH—59 °C, 30 s; AR—55 °C, 45 s; 
Bax—49 °C, 30 s; Bcl-2—64 °C, 30 s; Snail 58 °C, 45 s; 
Zeb 58 °C, 40 s). RQ-PCR reactions and visualisation were 
carried out as previously described [22].
Cell migration and invasiveness
Cell migration potential and invasiveness were assessed 
utilising standard Boyden transwell method (BD BioCoat 
Tumor Invasion System No. 354166, Poland) according to 
manufacturer’s instruction. For quantification of migrating 
cells post-invasion cell labelling with calcein was performed 
and fluorescence of invading cells was evaluated.
Statistical analysis
All data concerning proliferation, cytotoxicity or cell inva-
sion experiments represent the average of five wells in each 
experiment (n = 5). Data were expressed as mean ± stand-
ard deviation. In cases of RT-PCR and Western blot, each 
analysis was performed in triplicate. The significance of the 
differences between mean values were calculated using Stu-
dent’s t test or one-way analysis of variance and appropriate 
post hoc test (the ANOVA Kruskal–Wallis test). Differ-
ences are shown as significant at *p < 0.05, **p < 0.01 or 
***p < 0.001, as indicated.
Results
KR decreases proliferation of prostate cells 
depending on malignancy potential
The influence of KR treatment on PC cell proliferation was 
assessed. Three different cell lines derived from normal 
prostate gland—RWPE-1, WPMY-1 and PZHPV, as well 
as three cell lines derived from PC with different charac-
terisation—LNCaP (androgen dependent, low malignancy 
potential), Du145 (androgen independent, intermediate 
malignancy potential) and PC-3 (androgen independent, 
high malignancy potential) were used. Cells were treated 
with the indicated concentrations of KR for 48 or 72 h, and 
proliferation was assessed as described in “Methods” sec-
tion. As shown in Fig. 1a, KR is capable of inhibiting pros-
tate cell proliferation, which is dose- and time-dependent, 
at both concentrations. Also, a different response for KR 
treatment was observed for different cell types. The high-
est proliferation inhibition occurred in Du-145 and PC-3, 
whereas in non-carcinoid cell lines (RWPE-1, WPMY-1 and 
PZHPV) the effects were significantly weaker.
To further analyse the dependency of KR mediated pro-
liferation inhibition on malignancy potential, the effect of 
KR treatment on primary cell lines prepared and classified 
as described in “Methods” section was assessed. Similarly 
to previous experiments, KR inhibited proliferation of pros-
tate tissues in a time- and dose-dependent manner (Fig. 1b). 
KR diminished the proliferation to a greater extent in cells 
derived from tissues classified with higher Gleason score 
(G-score).
KR diminishes molecular traits of malignancy 
potential in prostate cancer cell lines
To elucidate molecular changes caused by KR treatment, 
PC cell lines (LNCaP, PC3, Du145, WPMY, RWPE and 
PZHPV) were treated with KR at concentration of 2,5 or 
5 μM for 48 and 72 h. Protein expression at mRNA and pro-
tein levels was assessed as described in “Methods” section. 
Results from WB and RT-PCR are presented in Figs. 2, 3, 
4, and 5.   
No full-length AR (fl-AR) expression in androgen insen-
sitive cell lines (PC3 and Du145) was indicated (data not 
shown). In androgen-sensitive cell line LNCaP, the KR 
efficiently diminished the expression of AR at both mRNA 
and protein levels, which were, dose dependent. Moreover, 
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decreased phosphorylation of AR at Ser 210/213 was 
observed after KR treatment.
A decrease of Akt protein level in each cell line was 
indicated, with the most prominent one in PC-3, and less 
visible in Du145 and WPMY-1. The protein level of Akt 
phosphorylated at Ser 473 was assessed and found to be sig-
nificantly decreased after KR treatment in each cell line. The 
effect on phosphorylation was the most prominent in Du145. 
Furthermore, the protein level of potent Akt phosphatase 
PTEN was increased in Du145, WPMY and RWPE, but not 
in LNCaP and PC3, as those cell lines are PTEN negative 
[25]. Additionally, PTEN phosphorylation at Ser 380 was 
enhanced by KR.
Next, Ras/Raf/EKR pathway proteins expression in 
PC-3, Du145, LNCaP and PZHPV was examined; KR 
treatment was found to have caused a decrease in each 
protein level, which corresponded with the decrease in 
respective mRNA amount.
Real-time PCR experiment was performed; it con-
firmed KR capability of diminishing the expression of 
AR and BCL-2, as well as of increasing BAD and BAX 
expression in prostate cell lines, which was more evident 
in cancerous cells (Fig. 6a, c).
Additionally, we evaluated the protein level of E-cad-
herin and E-cadherin phosphorylated at Ser838/840 in 
androgen-dependent LNCaP cell line, and showed that 
Fig. 1  Proliferation of a malig-
nant (LNCaP, PC-3, Du145) 
and non-malignant (PZ-HPV-7, 
RWPE-1, WPMY-1) human 
prostate cell lines and b primary 
cells—cancer G1, G2, G3, G4 
and normal. Cells were treated 
with 2.5 μM and 5 μM Kinetin 
Riboside (KR). The cells were 
cultured as indicated: in typical 
medium (control) or treated 
with KR solution for 48 h and 
72 h. The details are described 
in M&M. The results are given 
as the percentage of the control 
proliferation. Data represent 
mean values ± SD from three 
independent experiments. The 
significance was calculated 
using Student’s t test or one-
way analysis of variance and 
appropriate post hoc test (the 
ANOVA Kruskal–Wallis test). 
Differences are shown as sig-
nificant at *p < 0.05, **p < 0.01 
or ***p < 0.001
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KR treatment increased both total protein amount and its 
phosphorylation.
KR affects apoptosis in PC via Bcl‑2 family proteins
Our previous work showed that KR is a potent apoptosis 
activator [12]. The present results showing that KR was 
efficient in dose-dependent caspase activation in PC cell 
lines (Fig. 6a) are consistent with the previous reports. 
Caspases activation was predominantly present in cancer-
ous cells. As shown in Figs. 3a and 4a, this effect is at 
least partly dependent on dysregulation of Bcl-2 family 
proteins’ level. KR was efficient in lowering protein and 
mRNA level of antiapoptotic Bcl-2, while subsequently 
increasing it in case of proapoptotic Bad and Bax. This 
influence on Bcl-2 and Bad was most prominent in tum-
origenic Du145 and PC3 cell lines, and less evident in 
LNCaP and non-tumorigenic PZHPV.
KR reduces protein levels of EMT‑associated 
transcription factors
A major hallmark and one of the substantial changes during 
EMT is the up-regulations of EMT-associated TFs—Snail, 
Twist1, and Zeb. To elucidate the influence of KR on molec-
ular pathways governing EMT, its effect on the expression of 
those TFs was assessed. The results presented in Fig. 6b for 
protein amount and Fig. 2a for corresponding mRNA levels 
prove that KR is efficient in decreasing expression of Snail, 
Twist, and Zeb in each of the tumorigenic cell lines PC3, 
LNCaP, and Du145. Interestingly, no significant changes in 
normal PZHPV cell line were observed. These results were 
confirmed by real-time PCR experiment for Snail and ZEB 
(Fig. 6a).
KR inhibits migration potential of prostate cancer 
cell lines
As far as EMT is suggested to be implicated in increas-
ing cellular motility and invasiveness, especially in case 
of cancer cells, we aimed to assess the influence of KR on 
migration utilising Boyden transwell method as described in 
“Methods” section. Results are presented in Fig. 6d. Among 
untreated cells, migration was detected in case of PC-3 and 
Du145 (high migration rate), LNCaP (moderate migration 
rate) and PZHPV (very low migration rate). KR treatment 
efficiently decreased the amount of migrated cells in each 
cell line and this effect was dose dependent.
KR influence on molecular pathways correlates 
with G‑score
For a better insight into effects of KR on PC, mRNA level 
changes in primary cell lines triggered by KR were assessed. 
PCR analysis proved that KR efficiently diminished expres-
sion of mRNA for Bcl-2, MMP-2, MMP-9, Zeb, Snail, and 
Twist1, and increased BAX mRNA amount. Apart from 
MMP-9 mRNA, these changes were more prominent in 
cells derived from tissues characterised with higher G-score 
Fig. 2  Effect of KR on proliferation, migration and EMT markers 
in normal and cancer prostate cell lines (a) and primary cell lines 
(b): BAX, BCL-2, MMP-2, MMP-9, ZEB, SNAIL, TWIST and AR 
expression at mRNA level were determined by reverse transcription-
PCR after incubation with typical medium (control) or 5 μM KR for 
48 h. The upper lanes show the levels house-keeping gene GAPDH 
under the same culture conditions. Presented pictures are representa-
tives of at least three independent experiments with comparable 
results
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(Fig. 2b). Importantly, Zeb and Twist mRNA amount cor-
related positively with G-score in untreated cells.
Discussion
Our results indicate that KR is a compound capable of effi-
cient inhibition of PC cell proliferation, which is dose- and 
time-dependent. Interestingly, proliferation inhibition among 
cell lines in response to KR treatment is positively correlated 
Fig. 3  The effect of KR in human prostate cell lines on a the apop-
totic pathway regulated by members of Bcl-2 family (Bax, Bad, Bcl-
2); b the MAPK pathway (Ras, c-Raf, Erk1/2); c the EMT markers 
in transitional prostate cells (Snail, Twist, ZEB-1). Cells were treated 
with typical medium (control), 2.5 μM or 5 μM KR, as indicated and 
harvested after 72  h. β-actin was used as a protein loading control. 
Densitometry was used to normalise each proteins to β-actin protein 
level. Presented pictures are representative membranes of at least 
three independent experiments with comparable results
 Medical Oncology (2020) 37:17
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Fig. 4  The effect of kinetin riboside (KR) on a malignant (LNCaP, 
PC-3, Du145) human prostate cell lines: Western blot analysis for 
Akt, p-Akt(Ser 473), PTEN, p-PTEN(Ser380). b Non-malignant (PZ-
HPV-7, RWPE-1, WPMY-1) human prostate cell lines: western blot 
analysis for AR and p-AR(Ser210/213). Cells were treated as indi-
cated in “Methods” section and harvested after 72  h. Densitometry 
was used to normalise Akt, PTEN or AR to β-actin protein level, and 
phosphorylated Akt, PTEN or AR to total Akt, PTEN or AR and to 
β-actin protein level. Presented pictures are representative membranes 
of at least three independent experiments with comparable results. 
The histograms represent densitometry data (mean ± SD). Values are 
denoted as **p < 0.01 or ***p < 0.001
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with their malignancy potential. Furthermore, the results 
obtained for primary cell lines presented in Fig. 1b support 
this notion—KR diminished proliferation to a greater extent 
in cells derived from tissues classified with higher Gleason 
score (G-score) which correlates with malignancy. That fea-
ture of KR is unusual for other carcinostatics.
To elucidate the mechanism of KR action, we screened 
changes in the expression of proteins known for their impor-
tance in PC biology upon treatment with this compound. 
First, we assessed androgen receptor (AR). As mentioned, 
AR is important predominantly in the early phases of pros-
tate tumorigenesis, and with cancer progression it is often 
lost or changed, which may be advantageous for cancer cells. 
As expected, we found no full-length AR (fl-AR) expression 
in androgen insensitive cell lines characterised with high 
malignancy potential (PC3 and Du145; data not shown); 
however, the existence of AR variants (vAR) important 
in cancer progression in those cell lines [3] must be men-
tioned. In turn, the observed decrease of AR protein level 
in androgen-sensitive LNCaP cell line upon KR treatment 
may be partially responsible for proliferation inhibition in 
this cell line. Additionally, KR diminished phosphorylation 
of AR at Ser 210/213. This phosphorylation is thought to 
modulate AR mediated gene expression in a way beneficial 
for PC development, and its decrease may be attributed to 
inhibition of Akt known to target this site in AR to suppress 
AR-induced apoptosis [6].
Another protein thought to play an important role in PC 
progression, beside AR, is Akt. Akt signalling up-regulation 
is often a compensational event for androgen signalling loss 
at late stages of cancer development or during androgen 
deprivation therapy when it confers resistance towards this 
therapy. This pathway hyperactivity strongly correlates with 
malignancy potential [3, 5]. We proved KR to decrease total 
protein expression of Akt. Moreover, KR is highly efficient 
in inhibition of Akt activating phosphorylation at Ser 473, 
which is most evident in Du145. We indicated the increase 
in protein level of potent Akt phosphatase PTEN upon KR 
treatment. However, this may only partially explain Akt inhi-
bition as PTEN is up-regulated only in Du145, WPMY and 
RWPE, but not in LNCaP and PC3, as those cell lines are 
PTEN negative [25]. Moreover, the inactivating phospho-
rylation of PTEN at Ser 380 is enhanced by KR treatment. 
Interestingly this modification of PTEN was reported to sub-
sequently increase its stability and inactivate its phosphatase 
activity [26]. This is consistent with the observed increase 
in PTEN total protein level. On the other hand, the influence 
on enzymatic activity stays in opposition to the effects of KR 
on Akt. Moreover, as far as PC-3 is PTEN negative and yet 
most potent for KR mediated proliferation inhibition, it is 
unlikely that KR effects are mainly due to PTEN regulation. 
MAPK pathway with Ras, Raf, and Erk 1/2 being the most 
researched members, is the branch of cellular signalling that 
converges most proliferative signalling, thus its dysregula-
tion plays an important role in PC [5]. It is activated by many 
growth factors and other proproliferative cues. KR efficiently 
decreased the amount of Ras, Raf, and Erk 1/2 protein level 
in PC cell lines thus diminishing proliferative signalling 
transmission. Again, this effect was slighter in PC-3, which 
is consistent with its highest malignancy potential, and sug-
gests deeper dysregulation in molecular pathways. It would 
also be beneficial to assess the phosphorylation status of 
MAPK pathway in response to KR in the future.
Poor correlation between the influence on Akt or MAPK 
pathways and the excess of antiproliferative effect among 
cell lines suggest those may not be crucial molecular tar-
gets for KR carcinostatic activity. Alternatively, cell lines 
characterised with higher malignancy potential may be more 
dependent on those pathways, thus their inhibition may exert 
more prominent effects.
Importantly AR, MAPK, and Akt pathways are intercon-
nected via a complex crosslinking. Crosstalk between them 
is multidirectional and context-dependent. For instance, Akt 
was shown to enhance or diminish transcriptional activity 
of AR, which was context-specific and dependent on the 
evaluated target gene [27].
As mentioned above, EMT has been recently exten-
sively studied as a process involved in PC progression 
conferring metastatic potential, therapy resistance, and 
associated with poor prognosis. Although a precise pri-
mary mechanism underlying EMT induction is still elu-
sive, many molecular pathways are known to enhance this 
process. Among them, Akt and MAPK signalling seem to 
play an important role in PC [8]. Although AR itself was 
proved to enhance EMT-associated TFs (Snail, Twist, Zeb) 
expression, androgen deprivation is also a known factor 
promoting EMT, possibly through accompanying compen-
satory up-regulation of Akt and MAPK signalling [8]. The 
obtained results clearly indicate the involvement of TFs 
such as Snail, Twiest and Zeb in the regulation of EMT. 
In fact, the TFs are crucial for EMT to occur. The best 
-recognised EMT molecular hallmark is E- to N-cadherin 
switch. Other changes involve enhanced matrix metal-
loproteinases (MMPs) expression, which enables cancer 
cells to invade surrounding tissues, thus conferring migra-
tory and metastatic potential [9]. EMT-associated TFs, 
N-cadherin, and MMPs each may act in positive feedback 
loops activating other signalling pathways beneficial for 
cancer cells. It is important to note that EMT seems to be 
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positively correlated with malignancy potential in case of 
PC [28]. Finally, it is noteworthy that EMT is not a binary 
process with many intermediate states between epithelial 
and mesenchymal differentiation that in fact may be most 
beneficial for cancer survival and development. Molecular 
phenomena leading to these transient states are similar to 
those leading directly to EMT [9].
In our work, we proved that KR efficiently inhibited EMT 
TFs expression in all researched PC cell lines, hence poten-
tially inhibiting EMT.
Furthermore, KR inhibited migration of cells as assessed 
in Boyden chamber. This may be associated with the 
decreased motility resulting from EMT inhibition as well 
as the observed decreased MMPs expression after KR 
treatment. Interestingly, we did not observe any significant 
changes in EMT TFs and MMPs mRNA levels in normal 
PZHPV cell line, possibly because of its non-tumorigenic 
character resulting non-advanced EMT changes and lack of 
EMT activating signalling potent for inhibition.
Our results suggest that KR diminishes signalling through 
PI3K/Akt, MAPK, and AR in PC, although to a different 
extent in each cell line. Interestingly, in PC-3, which is char-
acterised with the highest malignancy potential, proliferation 
inhibition by KR was the most marked, although decrease 
in PI3K/Akt, MAPK, and AR pathways were not most evi-
dent. This suggests the primary target of KR to be different 
from the aforementioned pathways at least in PC-3. On the 
other hand, Snail, Twist, and Zeb were down-regulated in 
each cell line in response to KR, and the magnitude of this 
effect was positively correlated with malignancy potential 
and G-score, thus potentially explaining why KR exerts 
stronger antiproliferative activity in those cells. It is pos-
sible that at least in PC-3 EMT inhibition by KRs occurs 
upstream of other researched molecular changes, which are 
secondary to disruption of positive feedback loops formed 
due to EMT programme. This may explain why the antipro-
liferative effect of KR is greatest in cells characterised by the 
highest malignancy potential and most advanced EMT-like 
molecular. It is possible that up-regulation of EMT TFs is 
pivotal for PC development towards more malignant states, 
and during this process cancer cells grow more and more 
dependent on their activity.
Additionally, we showed KR to increase E-cadherin and 
phosphorylated E-cadherin (Ser838/Ser840) protein levels 
in LNCaP cell line. Increased E-cadherin amount may be 
the hallmark of EMT reversion by KR and is itself linked to 
reduced invasiveness and migratory potential. Furthermore, 
enhanced phosphorylation at Ser838/Ser840 was shown to 
strengthen cell–cell adhesion and increase E-cadherin/β-
Catenin interaction, thus decreasing WNT oncogenic sig-
nalling in tumour [29].
The KR influence on Bcl-2 family protein highlights the 
proapoptotic potential of this compound, which is consistent 
with our previous results. Interestingly, although KR univer-
sally causes an increase in proapoptotic Bax and Bak levels 
with subsequent decrease in antiapoptotic Bcl-2, the relative 
magnitude of these effects is different in each cell line. This 
is consistent with many reports that EMT TFs are able to 
modulate Bcl-2 family protein expression. Interestingly, it 
was also shown that Bcl-2 is not only up-regulated by EMT 
TFs, but its overexpression itself may induce EMT [30].
Our work highlights the efficacy of KR in EMT inhibition 
and, consequently, lowering metastatic potential. However, 
precise molecular mechanisms behind these phenomena are 
still elusive. Recently, KR was shown to act as neosubstrate 
for some kinases due to its similarity to ATP, which is pos-
sibly playing a physiological role in DNA damage response 
[31]. Off note, other compounds sharing structural similarity 
with KR are also known to act as distinct kinases inhibi-
tors [32–35]. Consistently, KR itself is a potent inhibitor of 
DNPH1—an enzyme suggested to play a role in tumorigen-
esis [36]. It is possible that KR also directly affects kinase 
activity in case of EMT inhibition. Finally, we can say that 
KR as well as other cytokinins can work in a similar way as 
antiproliferative effect was previously attributed to ROS gen-
eration, ATP depletion, differentiation induction and Bcl-2/
Bax balance modulation [19, 37]. On the other hand, kinetin 
itself is a potent antioxidant. Interestingly, kinetin was also 
reported to alter lipid bilayer properties [38] and to modu-
late mitochondrial respiration as observed by increase in 
transmembrane potential [39], which is in opposition to KR 
mediated effect [19]. Given the aforementioned importance 
Fig. 5  a The effect of kinetin riboside (KR) on non-malignant (PZ-
HPV-7, RWPE-1, WPMY-1) human prostate cell lines. Figure repre-
sents results of Western blot analysis for Akt, p-Akt(Ser 473), PTEN, 
p-PTEN(Ser380). Cells were treated as indicated in “Methods” sec-
tion and harvested after 72  h. Densitometry was used to normalise 
Akt or PTEN to β-actin protein level, and phosphorylated Akt or 
PTEN to total Akt or PTEN and to β-actin protein level. Presented 
pictures are representative membranes of at least three independ-
ent experiments with comparable results. The histograms represent 
densitometry data (mean ± SD). Values are denoted as **p < 0.01 or 
***p < 0.001. b Western blot analysis for E-cad and p-E-cad(Ser838/
Ser840). Androgen-dependent LNCaP cell lines were treated as indi-
cated in “Methods” section and harvested after 72  h. Densitometry 
was used to normalise E-cad to β-actin protein level, and phospho-
rylated E-cad to total E-cad and to β-actin protein level. Presented 
pictures are representative membranes of at least three independent 
experiments with comparable results. The histograms represent den-
sitometry data (mean ± SD) of three independent experiments. Values 
are denoted as **p < 0.01 or ***p < 0.001
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of ROS balance in EMT development, it is possible that 
these phenomena also play a role in its inhibition.
Other possible mechanisms comprise cdk1 and 2 inhibi-
tion, as well as AMPK activation, TRAF6 activity modu-
lation with following inhibition of Akt, TAK1 inhibition, 
and decreasing FPPS activity resulting in diminished Ras 
signalling [32–35]. Finally, although KR was proved not to 
be incorporated into DNA or RNA [14], it is possible that 
its biological activity may depend on direct interaction with 
transcriptional machinery due to its chemical similarity to 
other nucleosides.
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Fig. 6  Activation of either the 
EMT or apoptotic pathways 
after treatment the cells with 
KR 5 µM for 72 h: a RQ-PCR 
analysis of AR, Snail, ZEB and 
b BAD, BAX, BCL-2 tran-
scripts. To confirm the specific-
ity of the PCR products, melting 
curve analysis was performed. 
The measurements were per-
formed in triplicates accord-
ing to the standard  2−ΔΔCT 
method with GAPDH used as a 
calibrator. All primer pairs were 
initially validated by a passing 
test for equal amplification effi-
ciencies. The amplification effi-
ciency was close to 2. Statisti-
cally significant difference from 
the corresponding control are 
marked as follows: *p < 0.05, 
**p < 0.005 or ***p < 0.001. 
c Global caspase activity—
apoptosis pathway. The rate 
of apoptosis was estimated by 
caspase activity assay following 
48-h incubation as indicated. 
The data represent the mean of 
three independent experiments, 
expressed as the percentage of 
control activity. Significantly 
different from the correspond-
ing control are marked as fol-
lows: **p < 0.01, ***p < 0.001. 
d Migration through Matrigel-
coated Boyden chamber. 
Representative results of at least 
three independent experiments 
are presented
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